Ro.co vs MedVi: Compare GLP-1 Programs & Pricing
Side-by-side Ro.co and MedVi: semaglutide/tirzepatide starting prices, promos, membership rules, and official links.
Ro.co and MedVi are telehealth providers that connect patients with licensed clinicians for evaluation and prescribing of GLP-1–related therapies. This comparison focuses on program structure, starting prices where publicly available, promotions, membership requirements, and safety considerations so you can choose the option that best fits your needs.
Ro.co vs MedVi: Quick Overview
| Provider | Semaglutide | Tirzepatide | Promo | Membership |
|---|---|---|---|---|
| Ro.co | Not publicly listed | Not publicly listed | Brand med access | $145.00 — Yes |
| MedVi | $179.00 | $279.00 | $120 off first month | — No |
Note: Pricing for Ro.co’s GLP-1 options was not listed in the source input; MedVi’s published starting prices are shown and bolded here to highlight the lower available public rates in this comparison. Always verify current pricing directly on the provider site before enrolling.
Ro.co vs MedVi: Medical Process & Accessibility
Both providers operate under telehealth care models: an online intake, clinician review, and a prescription decision based on health history and clinical guidelines. Licensed clinicians evaluate safety, contraindications, and whether a GLP-1 medication is appropriate. Neither platform replaces in-person care when it is clinically indicated.
Ro.co vs MedVi: Pricing Comparison
MedVi lists semaglutide starting at $179.00 and tirzepatide starting at $279.00. Ro.co’s site does not list public per-dose starting prices in the provided inputs; instead Ro.co indicates a membership fee of $145.00 is required. Membership fees and pharmacy fulfillment can materially affect your out‑of‑pocket cost.
Promotions also matter: Ro.co notes “Brand med access” while MedVi advertises “$120 off first month.” If you expect to continue medication beyond an introductory month, compare monthly supply cost, shipping, pharmacy sourcing, and follow-up visit fees to estimate total program cost.
Ro.co vs MedVi: Clinical Oversight & Support
Both services provide clinician oversight, but approaches vary. Ro.co is often positioned for faster intake and rapid approvals, while MedVi emphasizes ongoing follow-up and dose optimization. Both rely on licensed U.S. clinicians who will not prescribe if there are safety concerns.
Ro.co vs MedVi: Medication Quality & Safety
Many telehealth platforms prescribe either branded FDA‑approved medications (for example, Wegovy® for semaglutide or Mounjaro® for tirzepatide when clinically appropriate) or compounded alternatives dispensed by partner pharmacies. Compounded medications are not identical to branded products; ask your clinician and pharmacist about source, formulation, and monitoring.
Ro.co vs MedVi: Customer Experience
Patient reports commonly highlight Ro.co for ease of signup and lower transparent fees when membership is accepted, and MedVi for attentive follow-up and personalized dose adjustments. Shipping and delivery timelines vary but are typically within a week of approval depending on pharmacy and location.
Read Ro.co Details
Read MedVi Details
Ro.co vs MedVi: Final Verdict
Choose Ro.co if you prefer a membership-based program that can streamline onboarding. Choose MedVi if you want publicly listed per-month medication pricing and no required membership. Both work with licensed clinicians and U.S. pharmacies; the best fit depends on budget, desired clinical touchpoints, and convenience.
Join Ro.co
Get Started with MedVi
Disclaimer
This article is informational only and not medical advice. Always consult a licensed clinician to determine whether GLP‑1 therapy is appropriate for you. FDA‑approved branded drugs such as Wegovy® (semaglutide) and Mounjaro® (tirzepatide) have specific indications; compounded products and telehealth-prescribed regimens may differ. Pricing, promotions, and membership details change frequently — verify details on the provider’s official site before enrolling.